The 47th San Antonio breast cancer Symposium (SABCS) in 2024, held in the United States from December 10 to 13, is one of the largest and most prestigious academic events in the field of breast cancer research. At this conference, Zhengda Tianqing focused on HR+/HER2- and triple negative breast cancer, and released a number of clinical research data based on arotinib. The objective response rate (ORR) of the triple negative breast cancer study, which is called "the most toxic breast cancer", is as high as 75.0%; The disease control rate (DCR) in the treatment of breast cancer patients with CDK4/6 inhibitor resistant HR+breast cancer was 94.9%.

Efficacy and safety of the first-line treatment of advanced triple negative breast cancer with arotinib combined with paianzulimab and albumin bound paclitaxel: a prospective, phase II clinical study

Forty three patients with inoperable locally advanced or recurrent/metastatic triple negative breast cancer (TNBC) with an ECOG PS score of 0-1 were included in the study. Eligible patients were treated with arotinib+paclitaxel+albumin conjugated paclitaxel, and the median follow-up time was 8.67 months. The objective response rate (ORR) for the primary endpoint of 40 patients with assessable efficacy was 75.0%, the disease control rate (DCR) for the secondary endpoint was 97.5%, the median progression free survival (PFS) was 10.64 months, and the median overall survival (OS) has not yet been reached. Among them, 1 patient achieved complete remission (CR), 29 patients achieved partial remission (PR), 9 patients had disease stability (SD), and 1 patient had disease progression (PD). [1]

Anerotinib combined with albumin binding paclitaxel based neoadjuvant chemotherapy for HER2 negative breast cancer: a prospective, single arm, single center, phase II clinical study

The study included 31 HR positive and HER2 negative breast cancer patients with ECOG PS 0-2 and no previous systematic treatment. Eligible patients received 5 cycles of arotinib+6 cycles of chemotherapy (albumin bound paclitaxel+anthracycline+cyclophosphamide) and then received surgery. As of June 30, 2024, 28 patients have received at least one treatment, and 27 patients have undergone surgical treatment. The primary endpoint was a total pathological complete response (tpCR) rate of 14.8%, a breast pathological complete response (bpCR) rate and an axillary pathological complete response (apCR) rate of 18.5%, and an objective response rate (ORR) of 92.9%. Among them, 4 patients achieved complete remission (CR), and 22 patients achieved partial remission (PR). [2]

A new choice in the post CDK4/6 inhibitor era: a multicenter real world study on the treatment of HR positive metastatic breast cancer resistant to CDK4/6 inhibitors with arotinib based combination regimen

This study retrospectively analyzed 53 patients with metastatic breast cancer who had received at least first-line CDK4/6 inhibitor treatment before disease progression and were confirmed to be HR positive and HER2 negative. The patients received arotinib treatment. The combined drugs included aribrin, albumin bound paclitaxel, etoposide, capecitabine, pabolizumab, cindilimab or fluvison. The median follow-up time was 9.2 months. The median progression free survival (PFS) of 39 patients with assessable efficacy was 7.1 months, the objective response rate (ORR) was 30.8%, and the disease control rate (DCR) was 94.9%. Among them, 12 patients achieved partial remission (PR), and 25 patients achieved disease stability (SD). [3]

Focusing on the field of breast cancer, Chia Tai Tianqing has launched innovative products such as Fluvastatin Injection, Docetaxel Injection, Evimox Tablets, Trastuzumab for Injection, Pipercelli Capsules, Aribrin Injection, etc. Among them, Elibulin Injection is a new variety approved for market in December this year. In addition, the company has also deployed various innovative drugs and biosimilars such as pertuzumab injection, CDK2/4/6 inhibitor kumoxili capsules, HER2 dual antibody ADC drug TQB2102, etc.